Well Referenced

Tag: itraconazole

Repurposed Itraconazole for Use in the Treatment of Malignancies as a Promising Therapeutic Strategy

This 2022 review evaluates itraconazole, a triazole antifungal, as a repurposed anticancer agent. Itraconazole demonstrates anti-tumor activity by inhibiting angiogenesis and multiple oncogenic signaling pathways, notably the Hedgehog pathway. Preclinical studies show its efficacy in various solid and hematological malignancies. Clinical trials have reported benefits in prostate, lung, and basal

Read More »
June 26, 2025 No Comments

Repurposing Drugs in Oncology (ReDO)—Itraconazole as an Anti-Cancer Agent

This 2015 ReDO project review highlights itraconazole’s potential as a repurposed anticancer agent. Itraconazole, a triazole antifungal, exhibits mechanisms relevant to oncology including inhibition of angiogenesis, suppression of the Hedgehog signaling pathway, and induction of autophagic growth arrest. Preclinical and clinical evidence supports its efficacy in prostate, non-small cell lung,

Read More »
June 26, 2025 No Comments

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

This 2013 phase II trial evaluated the antifungal drug itraconazole as a potential therapy for chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC). Forty-six patients were randomized to receive either low-dose (200 mg/day) or high-dose (600 mg/day) oral itraconazole. The primary endpoint was the 24-week prostate-specific antigen (PSA) progression-free survival

Read More »
June 26, 2025 No Comments